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ABSTRACT The respiratory intensive care Assembly of the European Respiratory Society is proud to
present a summary of several important sessions held at the International Congress in Paris in 2018. For
the highly esteemed reader who may have missed the Congress, a concise review was written on three
topics: the state-of-the-art session on respiratory critical care, hot topics in weaning and the best abstracts
in noninvasive ventilation.
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CONGRESS HIGHLIGHTS
RESPIRATORY INTENSIVE CARE
State-of-the-art session: respiratory critical care
In this session four experts in the field provided state-of-the-art lectures on topics that relate to the
ventilatory and non-ventilatory management of patients with acute and chronic respiratory failure.
Ventilatory support in patients with acute respiratory distress syndrome
Laurent Brochard (Toronto, ON, Canada) covered the topic of ventilatory and non-ventilatory management
in acute respiratory distress syndrome (ARDS), particularly in terms of preventing ventilator-induced lung
injury (VILI). The Berlin definition of ARDS includes severity stratification and excludes the term “acute
lung injury”, and provides better mortality prediction than previous definitions [1]. The clinical
significance of a “protective” ventilation strategy is well established as mortality is reduced by 22% when
tidal volumes are reduced from 12 to 6 mL·kg−1 [2]. There is also evidence for benefit to keep plateau
pressure below 35 cmH2O to reduce VILI in mechanically ventilated ARDS patients. There is no
unanimous consensus on how to titrate positive end-expiratory pressure (PEEP) to achieve safe alveolar
recruitment; recent guidelines support using an individualised approach [3]. A recent study failed to show
mortality reduction with the use of extracorporeal membrane oxygenation techniques, and this treatment
option should be considered on a case-by-case basis if protective ventilation is likely to be sufficient [4]. The
concept of the “baby lung” was discussed. Due to atelectasis and infiltration, a smaller portion of the lung is
aerated. Tidal volumes are currently set based on predicted body weight and the presence of a “baby lung”
would result in higher than expected tidal volumes per unit of open lung. Prone positioning increases the
size of the open lung and has been shown to reduce mortality in severe ARDS. It was suggested that it may
be better to tailor tidal volumes and pressures based on the size of the “baby lung” rather than on the
currently used predicted body weight [5]. In many of the studies cited in this lecture, chest computed
tomography (CT) scans were used to measure the size of the baby lung. This remains one of the challenges
of using this concept as chest CT scans are not routinely carried out in all ARDS patients.
Difficult and prolonged weaning
Leo Heunks (Amsterdam, the Netherlands) provided an overview of various strategies for weaning from
ventilation. As much as 40% of the time devoted to patients requiring invasive ventilation is spent on
weaning [6]. There is an absence of evidence to indicate the best method for a spontaneous breathing trial
(SBT). A survey of the attendants present in the lecture room showed that around half of the attendants
prefer T-piece weaning to predict whether a patient is ready to be extubated, but it should be noted that
this number is highly biased by selection bias due to physician preferences for attending such a session.
There is an open debate over which SBT technique best predicts post-extubation work of breathing, and
therefore the likelihood of extubation success. One systematic review suggested that pressure support
ventilation was more successful in predicting post-extubation work of breathing than T-piece weaning [7],
although biases due to the heterogeneity of the studies included in the meta-analysis should be considered.
Another study did not find a difference between noninvasive pressure support ventilation (NIV) and
noninvasive neutrally adjusted ventilatory assist (NAVA) in predicting extubation readiness [8]. NAVA was
associated with better patient–ventilator synchrony and greater patient comfort; however, this study had a
low statistical power. There is a clear need for good quality randomised clinical trials before we have a
definitive answer on which SBT method is best used to inform decisions about weaning [9].
Diaphragm activity and morphology may be associated with outcome of extubation. The pressure-generating
capacity of the diaphragm can be reduced after 3–4 days of mechanical ventilation [10]. Accordingly, in over
40% of invasively ventilated patients diaphragm thickness decreases by >10% at day 4 of mechanical
ventilation, and this finding is associated with a prolonged weaning time and longer stay in the intensive care
unit (ICU) [11]. Furthermore, after 3–4 days of controlled mechanical ventilation the capacity of the
diaphragm to generate pressure decreases by 25% [10] and histologically the diaphragm develops atrophy
with muscle protein loss and inflammation with muscle protein dysfunction [12]. Sepsis and malnutrition [13],
in addition to mechanical ventilation either under-assisting (increase in patient effort) or over-assisting (rest
and atrophy), are associated with diaphragm weakness. Diaphragm contractile activity progressively decreases
with the increase in ventilator driving pressure applied. This supports the importance of using
diaphragm-protective mechanical ventilation to improve outcomes for invasively ventilated ICU patients [14].
Leo Heunks discussed several pharmacological strategies and inspiratory muscle training as adjuncts to
weaning from ventilation. As yet, there are no drugs licensed for improving respiratory muscle function.
The calcium sensitiser levosimendan has been shown to improve diaphragm function, but there are no
clinical trials to suggest its clinical benefit [15]. One systematic review suggests that inspiratory muscle
training improves the strength of inspiratory and expiratory respiratory muscles; however, the effects on
clinical outcomes remain to be established [16].
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Noninvasive respiratory strategies for acute respiratory failure
Stefano Nava (Bologna, Italy) gave an overview of the most frequently used noninvasive respiratory
support strategies for acute respiratory failure, which include supplementary conventional oxygen,
high-flow nasal cannula (HFNC) and NIV. Invasive ways to support patients with acute respiratory failure
include extracorporeal carbon dioxide removal (ECCO2R) and invasive ventilation. The choice between
these options depends on the type of respiratory failure, the severity of patients’ conditions and the
availability of resources.
Supplementary oxygen should be used with caution in hypercapnic chronic obstructive pulmonary disease
(COPD) patients, especially in preclinical settings, due to the increased risk of death [17] and potentially fatal
rebound hypoxaemia upon abrupt removal [18]. Conservative supplementary oxygen, targeting an arterial
oxygen saturation measured by pulse oximetry of 95–97%, has favourable outcomes and the unnecessary use
of a higher inspiratory oxygen fraction could decrease the probability of 60-day survival [19].
A physiological study comparing HFNC with NIV in stable COPD showed that a reduction in work of
breathing was best achieved with NIV [20]. The only randomised clinical trial comparing HFNC with NIV
in COPD with moderate hypercapnic failure showed that both strategies are equally effective [21]. HFNC
has been tested in patients with community-acquired pneumonia [22], after cardiothoracic surgery [23],
after extubation [24], and in acute hypoxaemic respiratory failure, but all trials failed to show more
favourable outcomes with HFNC. It must be noted that a different control group was used in each of the
studies, ranging from NIV to conventional supplemental oxygen therapy.
The use of NIV in COPD patients with acute or acute on chronic respiratory failure with acidosis (pH
<7.35) remains the gold standard and is strongly recommended [25]. However, NIV should not be used in
patients with severe hypoxic respiratory failure irrespective of the underlying diseases and should be used
with extreme caution in patients with ARDS irrespective of the severity of the oxygenation [26]. NIV failure
and delayed intubation increase the risk of death in acute de novo hypoxic respiratory failure [27, 28].
ECCO2R is still experimental in this patient population and is usually used as an adjunctive nonventilatory
option in patients with COPD who are failing or are at high risk of failing NIV, and as a means to
facilitate extubation in hypercapnic subjects. A systemic review showed that the combined use of ECCO2R
and NIV leads to dramatic improvements in arterial carbon dioxide tension (PaCO2), pH and respiratory
rates [29]; however, severe complications like bleeding, thrombocytopenia, circuit clotting and pump
malfunction are major issues.
There is no lower limit of pH at which a trial of NIV is inappropriate in patients with COPD [25] and
invasive ventilation should be used as a last resort. However, the lower the pH, the higher the risk of
failure, and patients must be very closely monitored with the possibility for rapid intubation in a protected
environment.
Noninvasive ventilatory strategies in stable COPD
The presentation by Wolfram Windisch (Cologne, Germany) focused on the evolution of ventilatory
strategies in stable COPD, the effectiveness of long-term NIV with low and high pressures, and therapeutic
outcomes of home NIV. The first consensus on use of long-term NIV in stable hypercapnic COPD patients
dates back to 20 years ago [30]. One landmark trial on the use of long-term NIV showed that patients
with slowly progressive restrictive diseases had fundamentally lower mortality rates when compared with
COPD patients [31]. Earlier studies showed no benefit of long-term NIV in stable COPD [32–34], which
may be due to the ventilatory strategy used at that time, based on the application of low pressures of
∼12–15 cmH2O.
Long-term NIV with low pressures (or “low-intensity NIV”) is not capable of decreasing PaCO2, and may
even worsen quality of life [35]. Long-term NIV with higher pressures (“high-intensity NIV”) is much
more capable of improving carbon dioxide retention, quality of life and even survival in selected stable
patients [36]. In general, long-term high-intensity NIV does not adversely affect cardiac performance, but
in patients with pre-existing heart failure, the application of very high pressures may result in a reduction
in cardiac output [37]. Failure in the improvement of hypercapnia is clearly associated with the worst
outcomes of long-term NIV. Long-term NIV in patients with persistent hypercapnia following acute NIV
can prolong time to readmission, and even result in death [38].
New trends in the management of difficult-to-wean patients
This symposium provided profound insights into the potential of a multidisciplinary approach to patients
with chronic critical illness. More specifically the topics of weaning and rehabilitation were discussed.
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Prolonged mechanical ventilation: definition and outcome
Laurent Brochard discussed classifications, causes and long-term outcomes of weaning from mechanical
ventilation.
The Consensus Conference on weaning [39] was reviewed. Weaning is classified into three categories:
1) simple weaning (defined as a patient being weaned on the first attempt with no difficulties); 2) difficult
weaning (a patient who failed a first weaning attempt and subsequently required up to three attempts or
up to 1 week in duration to be weaned); and 3) prolonged weaning (patients who are still
ventilator-dependent after 1 week or more than three attempts).
Failing to promptly identify patients who fall into the “simple weaning” category will increase the
probability of long-term mechanical ventilation dependence. Acknowledging and understanding the cause
of a “difficult to wean” patient is a crucial issue to prevent a patient from transitioning into a “prolonged
weaning” phase.
A more recent classification, based on a prospective multicentre study (the WIND study), was presented [40].
This new classification exhibits a progressive increase in mortality rate with the transition through weaning
classifications: 6%, 17% and 29% for group 1 (simple weaning), group 2 (difficult to wean) and group 3
(prolonged weaning), respectively. Subsequent days of mechanical ventilation was associated with an
increase in the probability of death, reaching up to 40% in patients who were still ventilated 10 days after
the first weaning attempt. In contrast to the Consensus Conference classification [39], the WIND criteria
[40] allows clear categorisation of all ventilated patients.
The cause of difficult weaning was attributed to a number of factors, with the diaphragm being a key focus.
Diaphragm weakness has been found to be strongly associated with difficult or prolonged weaning [41]. This
study included 76 patients, and at the time of a first weaning attempt, diaphragm weakness was reported in
63% of patients, whereas only 34% of patients had limb muscle weakness. Interestingly, only 21% of patients
had a combination of both diaphragmatic and limb muscle weakness. The iatrogenic role of mechanical
ventilation to induce early diaphragm weakness has been recently demonstrated [42]. In this study, patients
with progressive diaphragm atrophy (assessed with ultrasound) showed a higher probability of not being
separated from the ventilator, thus being classified as difficult to wean or prolonged weaning patients.
Regarding long-term outcomes, HERRIDGE et al. examined outcome measures in ARDS [43] and ICU
patients who had been ventilated for 1 week [44]. Time spent on mechanical ventilation (greater than or
less than 2 weeks) and patient age (greater than or less than 65 years) were identified as the factors able to
significantly influence long-term outcome, delineating four groups, which differed in terms of number of
deaths and home discharge. A meta-analysis looking at all studies performed in critically-ill patients
ventilated for at least 2 weeks, mirrored these findings [45].
A new ongoing multicentre prospective observational study endorsed by the European Respiratory Society
(ERS) and European Society of Intensive Care Medicine (the WEAN SAFE study) aims to better
understand weaning practices and outcomes in ICU patients. Results from this trial are expected soon.
Why can my patient not be weaned from the ventilator?
In the second presentation, Leo Heunks focused on the possible causes of weaning failure and the most
appropriate solutions. Overall this presentation provided a holistic approach to considerations of weaning
failure.
An ABC approach to difficult weaning was illustrated [46, 47], which aims to facilitate early recognition of
the potential causes and factors associated with a failed SBT. It was highlighted that being able to identify the
underlying causes of failure may significantly increase the chances of SBT success on subsequent attempts.
The ABC approach can be summarised in five domains: a) airway/lung, b) brain/cognition, c) cardiac
dysfunction, d) diaphragm and respiratory muscles, and e) endocrine/metabolic. Examples of relevant
causes and possible solutions for this ABC approach are provided in the following sections.
a) Airway/lung
Tracheostomy malposition, defined as greater than 50% occlusion of the distal lumen determined by the
posterior tracheal wall, may contribute to difficult weaning [48]. Performing a bronchoscopy while the
patient is disconnected from the ventilator could be useful to identify and correct it.
High airway resistances (such as those seen in COPD patients) can be solved by optimising
bronchodilation therapy.
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Low lung compliance can also cause SBT failure. Interestingly, pleural effusion eradication is recommended
to reduce a patient’s respiratory effort, despite a recent study failing to demonstrate if a difference in terms of
success/failure of the SBT was associated with presence/absence of pleural effusions [49].
b) Brain/cognition
Patients suffering from depressive disorders were found to spend more time in the process of weaning [50],
while treating them seemed to expedite liberation from mechanical ventilation.
c) Cardiac dysfunction
The transition from positive to negative intrathoracic pressure may favour the occurrence of
weaning-induced pulmonary oedema [51]. This may be more pronounced in COPD patients because
of higher airway resistances, which results in greater changes in intrathoracic pressure and the work of
breathing [52].
Pulmonary capillary wedge pressure (PCWP) >18 mmHg is the gold standard to identify a pulmonary
oedema occurring during an SBT, but it is not frequently used in clinical practice [51]. An increase in
brain natriuretic peptide during weaning has 76% sensitivity and 78% specificity in detecting cardiac
dysfunction and an increase in haemoglobin of 6% at the end of the SBT has a sensitivity of 81% and a
specificity of 100% in detecting pulmonary oedema related to the SBT [53], and these might be more
appropriate clinical measurements.
Maintaining a systolic blood pressure <140 mmHg (and a stable PCWP) during an SBT may increase the
likelihood of passing it and being successfully extubated [54]. Even in the absence of a positive medical
history for cardiac disorders, it could be worth considering cardiac failure in a difficult-to-wean patient.
d) Diaphragm and respiratory muscles
The development of respiratory muscle weakness is very frequent in weaning patients. In the section on
“Difficult and prolonged weaning” we already described several causes for diaphragm weakness.
Diaphragm weakness can be screened by measuring maximal inspiratory pressures, or with ultrasound
either measuring diaphragm excursion [55] or diaphragm thickness change during inspiration (thickening
fraction). Changes in oesophageal pressure (measured with an oesophageal catheter) during an SBT,
especially if combined with an electromyogram, were suggested to be useful, but the application of such
techniques into routine practice needs to be questioned. Few strategies can be applied to improve
diaphragm contractility. To date, no drug has been approved to improve respiratory muscle function [56],
but pilot studies indicate that inspiratory muscle training may be an effective strategy.
e) Endocrine/metabolic
It was recommended to screen patients for adrenal insufficiency, thyroid dysfunction and to assess
nutritional status, especially if weaning is transitioning from “difficult to wean” to “prolonged weaning”.
Evaluation of swallowing dysfunction and treatment with Passy–Muir valve
Christina Iezzi (London, UK) provided detailed insights into ICU-acquired dysphagia. Aspiration,
particularly silent, is the leading cause of pneumonia in ICU patients and contributes significantly to
morbidity and mortality.
The prevalence of ICU-acquired dysphagia is high across a variety of patient groups; with the literature
illustrating a prevalence of 91% in critical illness neuropathy [57], 42% in trauma patients intubated for
over 48 h [58], 52% in tracheostomised patients [59], and up to a third in ARDS survivors [60]. The
increasing prevalence has also been associated with less mortality during the acute phase of disease and
consequent prolonged ICU stay, together with an increased awareness and understanding of dysphagia.
The duration of invasive mechanical ventilation (in particular more than 7 days) and the occurrence of
re-intubation were found to be significant risk factors for post-extubation dysphagia [61]. The presence of
a tracheostomy is not a sole cause of dysphagia, but when in situ with an inflated cuff, symptoms may be
exacerbated and cause an accumulation of secretions with laryngeal/pharyngeal desensitisation.
The most reliable method of assessing swallowing function in patients is fibre-optic endoscopic evaluation
of swallowing (FEES) or videofluoroscopy. Videofluoroscopy is the gold standard but requires that patients
be transported outside the ICU. FEES is a well-tolerated and safe diagnostic test, which provides
information on secretion management, laryngopharyngeal reflux and airway patency. FEES is documented
to have a role in weaning, through the decision about tracheostomy downsizing or decannulation it can
facilitate to individualise the optimal feeding route for a patient.
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The early introduction of one-way valves in the weaning process has multiple benefits. One such device,
the “Passy–Muir”, is able to restore verbal communication and physiological PEEP, improve taste and
smell, and facilitate lung recruitment [62]. However, it was highlighted that, for a one-way valve to be
tried, a patient must have a patent airway and be able to tolerate cuff deflation. As a result, factors such as
upper airway obstruction and laryngeal oedema must be excluded first.
Challenges associated with whole body rehabilitation in difficult-to-wean patients
The final presentation was given by Michele Vitacca (Gussago, Italy) who addressed the challenges
associated with whole body rehabilitation in difficult-to-wean patients.
Typically, difficult-to-wean patients are aged, highly dependent, isolated, and may experience pain and
fatigue, a loss of functions, anxiety, depression and delirium. They are likely to have experienced
prolonged mechanical ventilation and ICU stay and periods of bed rest. This group of patients is prone to
developing infections, sepsis, malnutrition and muscle loss, complications and several comorbidities.
An early multidisciplinary rehabilitation programme can be safely and successfully started in both
unconscious critically-ill patients and stable cooperative patients. Rehabilitation programmes have been
found to have beneficial effects on ventilation, peripheral perfusion, metabolism, immunity, the prevention
of deconditioning, ICU weakness, thrombosis, bedsores, delirium, and on improving the rate of weaning
success [63–68]. Results seem to be influenced by the level of disability, comorbidities, type and stage of
disease, critical illness, consciousness and cooperation.
For optimal outcomes a successful rehabilitation programme will have multiple components including
bronchial hygiene techniques, peripheral and respiratory muscle training, and physical and occupational
activity. Neuromuscular electrical stimulation could also be a useful synergic method of improving muscle
effort, reducing muscle atrophy and maintaining muscle circumference [65]. There remains a lack of
consensus regarding the timing, modality and duration of an optimal rehabilitation programme and
therefore the benefits gained over time.
Several potential obstacles may bear upon the initiation and delivery of a rehabilitation programme,
including the presence of vasoactive support, staff and equipment resources, safety, and ability to deliver
early mobilisation.
Future developments in this important area include the identification of potential subgroups of patients
who are more likely to benefit, and the development of guidelines for a tailored rehabilitation approach to
include standardised timing, volumes and modalities of intervention.
Hot topics in NIV
Most abstracts in the “Hot topics in NIV” session focused on chronic hypercapnic respiratory failure in
COPD patients. However, studies on other indications (acute respiratory failure), other patient cohorts
(amyotrophic lateral sclerosis (ALS) and obesity hypoventilation syndrome (OHS)) and ventilator devices
were also presented.
High-intensity NIV
In COPD patients with severe chronic hypercapnia, mortality may be decreased by NIV due to lowering
PaCO2 [69]. High-intensity NIV has been shown to be able to significantly decrease elevated PaCO2 levels and
thereby improve other outcome parameters such as quality of life. However, higher inspiratory positive airway
pressure (IPAP) values may have side-effects such as excessive mask leakage. GUAN et al. [70] investigated the
physiological effects of high-intensity NIV in 12 COPD patients using a diaphragm electromyogram and
other respiratory physiological parameters such as oesophageal pressure. Due to these measurements, a more
individualised adjustment of pressure support was applicable in stable hypercapnic COPD patients.
Structured discharge and follow-up after discharge
Hospital readmission due to exacerbation is known to increase mortality in COPD [69]. ERGAN et al. [71]
presented the interim analysis of a structured discharge and follow-up protocol on readmission rate in 112
COPD patients receiving home mechanical ventilation (HMV) or long-term oxygen therapy. A trend
towards a reduced hospital readmission rate within 90 days was detected if patients received education on
the underlying disease and their NIV device, in combination with follow-up phone calls and a control visit
within 30 days as compared to standard therapy alone.
Mental support for COPD patients with depression or anxiety
COPD patients commonly suffer from comorbidities such as depression and anxiety, both of which are
related to dyspnoea [69]. VOLPATO et al. [72] provided their patients with short-term psychological support
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such as counselling, relaxation and mindfulness-based exercises during adaption to NIV. Quality of life
(EuroQol-5D) and illness perception were improved compared to the group without psychological support.
Overall, this led to higher adherence to NIV with an increased rate of acceptance of the ventilator support.
A handheld NIV device limits anxiety but not dyspnoea
Dyspnoea is one of the contributing factors for anxiety and depression in patients with COPD, who can be
extremely limited in their daily activities and experience social isolation. Bronchodilators and pulmonary
rehabilitation (PR) improve patients’ well-being by reducing dyspnoea and increasing exercise tolerance.
More recently, a portable, handheld NIV device (Vitabreath, Philips Respironics, Eindhoven, the
Netherlands), delivering patient-breath initiated fixed pressure (IPAP 18 cmH2O, expiratory positive
airway pressure 8 cmH2O) was shown to decrease recovery time in patients with COPD following exercise
in a PR centre [73]. LANE et al. [74] assessed the impact of the home use of Vitabreath in patients with
moderate–severe COPD, who had previously undergone PR, over a 12-week period. The device was well
accepted and reported to be easy to use. Furthermore, most patients described reduced anxiety around
dyspnoea, and improved breathlessness recovery time, despite no real changes occurred in frequency of
dyspnoeic events.
Long-term outcomes of OHS treated with NIV
OHS is among the most common indications for HMV, but it is unclear whether this condition needs to
be treated with NIV or if continuous positive airway pressure (CPAP) could be sufficient. This issue has
been previously tackled in short-term studies, which showed the superiority of NIV and CPAP compared
to lifestyle modification, but no differences between these two treatments emerged [75–77]. SANCHEZ
QUIROGA et al. [78] presented the results of the Pickwick randomised controlled trial, a large multicentre
study comparing long term outcome in patients with OHS and severe sleep apnoea treated with NIV or
CPAP. No differences in healthcare resource utilisation were observed between groups. In particular,
incidence of cardiovascular events was similar between arms, as well as the number of hospitalisations and
hospital days for all-causes. In line with previous results, it was shown that adherent patients (usage ⩾4 h
per night) had better outcomes compared to poorly compliant patients.
Home initiation of NIV
HMV is often used in patients with neuromuscular diseases like ALS to improve quality of life [79].
However, HMV can have a significant psychological impact on patients and an increased burden on
caregivers, especially as HMV initiation requires a dedicated hospital admission or several outpatient
appointments [80]. VOLPATO et al. [72] presented a non-inferiority trial comparing NIV initiation at home
and in the outpatient setting. All patients, regardless their randomisation arm, were started on NIV by the
same group of experienced physiotherapists. No differences in the main respiratory outcomes and quality
of life were observed, but a significant improvement in the caregiver burden was associated with NIV
initiation in the home setting.
Dexmedetomidine for sedation during acute NIV
Another indication for NIV is acute respiratory insufficiency. BIELKA et al. [81] compared adults with acute
respiratory insufficiency due to ARDS (mild–moderate according to the Berlin definition) on NIV with
and without the use of dexmedetomidine for sedation. This intervention led to improved patient comfort,
and lower incidences of delirium and post-traumatic stress disorders after ICU discharge. However,
common side-effects such as hypotension and bradycardia were seen in the treatment group.
Summary
In summary, this session highlighted the importance of a patient-centred approach to NIV for optimising
adherence to treatment, which will also result in better outcomes in both the acute and chronic setting.
Despite the different settings and patient cohorts, all the studies showed that it is very important to focus on
physiological variables, but also on improving patients’ education, comfort and overall wellbeing. All of this
allows an increased compliance with treatment, which results in better short- and long-term outcomes.
Concluding remarks
The authors of this article hope that this comprehensive summary of recent advances in respiratory
intensive care creates curiosity to follow-up on topics of interest to the reader. We are committed to
meeting the needs of our members and it is our hope that they will want to get more closely involved in
the society. We also hope to have encouraged the readership to attend the ERS International Congress
2019 in Madrid.
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